Insight Molecular DiagnosticIMDX
13F holders, Q4 2024 (December 31)26holders +6
4new positions
1sold out
$2.38avg. 13F price*
At the end of Q4 2024, 26 institutions reported holding Insight Molecular Diagnostic (IMDX) in their 13F filings, up 6 from Q3 2024. 4 opened new positions and 1 sold out. The largest holders were Broadwood Capital Inc. ($14.9M), AWM Investment Company, Inc. ($1.8M) and Pura Vida Investments, LLC ($1.6M).
- Company
- Insight Molecular Diagnostic
- Filed as
- ONCOCYTE CORP (Q4 2024)
- CUSIP
- 68235C206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $61K |
| Exits | 1 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 1,544,676 shares bought and 336,045 shares sold, net +1,208,631 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 26 holders
| Broadwood Capital Inc. | 1.16% | Add +26.7% | 6,244,405 | $14.9M |
| AWM Investment Company, Inc. | 0.23% | Reduce -29.3% | 775,804 | $1.8M |
| Pura Vida Investments, LLC | 8.61% | Add +32.1% | 654,451 | $1.6M |
| Vanguard Group Inc. | 0.00% | Reduce -1.3% | 242,206 | $576K |
| Geode Capital Management, LLC | 0.00% | Add +31.8% | 137,069 | $326K |
| BlackRock, Inc. | 0.00% | Add +0.2% | 79,957 | $190K |
| Morgan Stanley | 0.00% | Reduce -14.6% | 61,708 | $147K |
| Wealthedge Investment Advisors, LLC | 0.06% | — | 52,732 | $126K |
| FNY Investment Advisers, LLC | 0.06% | Add +15.1% | 49,377 | $117K |
| State Street Corp. | 0.00% | No change | 19,554 | $47K |
| Northern Trust Corp. | 0.00% | Reduce -0.1% | 17,333 | $41K |
| Two Sigma Securities, LLC | 0.01% | New | 13,215 | $31K |
| Ground Swell Capital, LLC | 0.06% | New | 10,915 | $26K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +198.3% | 4,313 | $10K |
| UBS Group AG | 0.00% | Add +225.0% | 2,714 | $6K |
| Lee Danner & Bass Inc. | 0.00% | New | 1,388 | $3K |
| Bank of America Corp. | 0.00% | Add +5.8% | 436 | $1K |
| Wilmington Savings Fund Society, FSB | 0.00% | No change | 250 | $595 |
| BNP Paribas Financial Markets | 0.00% | New | 208 | $495 |
| JPMorgan Chase & Co. | 0.00% | Add +26.6% | 195 | $465 |
| SBI Securities Co., Ltd. | 0.00% | — | 185 | $440 |
| Osaic Holdings, Inc. | 0.00% | Reduce -83.2% | 182 | $431 |
| Piscataqua Savings Bank | 0.00% | No change | 25 | $59 |
| Coppell Advisory Solutions LLC | 0.00% | No change | 10 | $24 |
| Albion Financial Group | 0.00% | No change | 7 | $17 |
| Danske Bank A/S | 0.00% | No change | 1 | $2 |
"% of holder's portfolio" is IMDX's weight in each manager's 13F, not the share of Insight Molecular Diagnostic the manager owns.